[
  {
    "ts": null,
    "headline": "3 Stocks Seeing Insider Buys: CNC, PFE, BMY",
    "summary": "Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.",
    "url": "https://finnhub.io/api/news?id=e46c046c1ceaf5425547ced00f3ce400599f0e15c65f542e18a01c320094a08c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731454800,
      "headline": "3 Stocks Seeing Insider Buys: CNC, PFE, BMY",
      "id": 131315773,
      "image": "https://media.zenfs.com/en/zacks.com/b56da65365e8609db11bbb1e13b32e44",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.",
      "url": "https://finnhub.io/api/news?id=e46c046c1ceaf5425547ced00f3ce400599f0e15c65f542e18a01c320094a08c"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot",
    "summary": "Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral density loss.",
    "url": "https://finnhub.io/api/news?id=f0146e5eb4d6695cb3e4ceda132f5b1221dd7b4924810a0c08a6f35462fe4078",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731447538,
      "headline": "Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot",
      "id": 131313959,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral density loss.",
      "url": "https://finnhub.io/api/news?id=f0146e5eb4d6695cb3e4ceda132f5b1221dd7b4924810a0c08a6f35462fe4078"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
    "summary": "Sector Update: Health Care Stocks Decline Late Afternoon",
    "url": "https://finnhub.io/api/news?id=4ae8b4d9d01c61272c975f2778b655c3e6d7403d95cb68b8b1af75daabf58149",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731445036,
      "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
      "id": 131312889,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Sector Update: Health Care Stocks Decline Late Afternoon",
      "url": "https://finnhub.io/api/news?id=4ae8b4d9d01c61272c975f2778b655c3e6d7403d95cb68b8b1af75daabf58149"
    }
  },
  {
    "ts": null,
    "headline": "Build a Balanced Portfolio With 4 Top Value Stocks as Markets Surge",
    "summary": "Value investing is essentially about selecting stocks that are cheap but fundamentally sound. STNE, SKX, PFE and GM boast a low P/CF ratio.",
    "url": "https://finnhub.io/api/news?id=05f9ce04cb9fdab4e7b81c50f8783290dc9b959978cf6300ed6d35519456bc79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731441600,
      "headline": "Build a Balanced Portfolio With 4 Top Value Stocks as Markets Surge",
      "id": 131313490,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Value investing is essentially about selecting stocks that are cheap but fundamentally sound. STNE, SKX, PFE and GM boast a low P/CF ratio.",
      "url": "https://finnhub.io/api/news?id=05f9ce04cb9fdab4e7b81c50f8783290dc9b959978cf6300ed6d35519456bc79"
    }
  },
  {
    "ts": null,
    "headline": "Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals",
    "summary": "Novavax sees Sanofi deal as path forward for company into profitability.",
    "url": "https://finnhub.io/api/news?id=ea6d77ddca71c020997eacc8875d46b4708e709e38e344f798a4a2bc55ea9464",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731440590,
      "headline": "Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals",
      "id": 131310041,
      "image": "https://s.yimg.com/ny/api/res/1.2/L_paiH5PSqCa4kA0g_2cCQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05MDA-/https://s.yimg.com/os/creatr-uploaded-images/2021-06/1f18aa40-cd50-11eb-976f-18ecd0587655",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novavax sees Sanofi deal as path forward for company into profitability.",
      "url": "https://finnhub.io/api/news?id=ea6d77ddca71c020997eacc8875d46b4708e709e38e344f798a4a2bc55ea9464"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=9ea2837cfa8513888ca5e7bb2ba14740b8eb90af5eee5ca63d6a7f358a835a04",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731429540,
      "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "id": 131416306,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=9ea2837cfa8513888ca5e7bb2ba14740b8eb90af5eee5ca63d6a7f358a835a04"
    }
  },
  {
    "ts": null,
    "headline": "Exclusive-Pfizer explores sale of hospital drugs unit, sources say",
    "summary": "Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three people familiar with the matter.  The unit, now called Pfizer Hospital, was formed after Pfizer bought Hospira for about $17 billion in 2015.  The pharma giant has hired Goldman Sachs to gauge initial interest from potential buyers, which include private equity firms and other pharmaceutical companies, the sources said, requesting anonymity as the discussions are confidential.",
    "url": "https://finnhub.io/api/news?id=519870bda87395744f125817c1de1969f9857102eef15209d711af8cff5da172",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731422848,
      "headline": "Exclusive-Pfizer explores sale of hospital drugs unit, sources say",
      "id": 131315778,
      "image": "https://media.zenfs.com/en/reuters-finance.com/bb32fe79795c71a60057270201aab39f",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three people familiar with the matter.  The unit, now called Pfizer Hospital, was formed after Pfizer bought Hospira for about $17 billion in 2015.  The pharma giant has hired Goldman Sachs to gauge initial interest from potential buyers, which include private equity firms and other pharmaceutical companies, the sources said, requesting anonymity as the discussions are confidential.",
      "url": "https://finnhub.io/api/news?id=519870bda87395744f125817c1de1969f9857102eef15209d711af8cff5da172"
    }
  },
  {
    "ts": null,
    "headline": "Should Value Investors Buy Pfizer (PFE) Stock?",
    "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
    "url": "https://finnhub.io/api/news?id=4ef5f67c4c8b75c9e87c6751fdce582e2094eac0d564967bb41c7aa7727a793f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731422417,
      "headline": "Should Value Investors Buy Pfizer (PFE) Stock?",
      "id": 131315779,
      "image": "https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
      "url": "https://finnhub.io/api/news?id=4ef5f67c4c8b75c9e87c6751fdce582e2094eac0d564967bb41c7aa7727a793f"
    }
  },
  {
    "ts": null,
    "headline": "Down -9.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)",
    "summary": "Pfizer (PFE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.",
    "url": "https://finnhub.io/api/news?id=5a19e29a1842378ec6a23b4afd04641c65f0ae8bdc6ebc5b79638b88293451cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731422106,
      "headline": "Down -9.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)",
      "id": 131315780,
      "image": "https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.",
      "url": "https://finnhub.io/api/news?id=5a19e29a1842378ec6a23b4afd04641c65f0ae8bdc6ebc5b79638b88293451cd"
    }
  },
  {
    "ts": null,
    "headline": "Keurig Dr Pepper taps new CMO to accelerate digital-first marketing",
    "summary": "Drew Panayiotou, most recently of Pfizer, is tasked with embracing new technology and keeping up momentum for brands like Dr Pepper.",
    "url": "https://finnhub.io/api/news?id=c63ac6eaea9ad7e572394240a16e616ed5d3a14d559bd635bc3b3d7505ef9a9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731407820,
      "headline": "Keurig Dr Pepper taps new CMO to accelerate digital-first marketing",
      "id": 131311412,
      "image": "https://imgproxy.divecdn.com/9Xvj55kwte4OCEBA_AzEToDZLBoZHgHT_MDd1a-Ivso/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9ob21lLWRyLXBlcHBlci10cnVjay5wbmc=.webp",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Drew Panayiotou, most recently of Pfizer, is tasked with embracing new technology and keeping up momentum for brands like Dr Pepper.",
      "url": "https://finnhub.io/api/news?id=c63ac6eaea9ad7e572394240a16e616ed5d3a14d559bd635bc3b3d7505ef9a9a"
    }
  },
  {
    "ts": null,
    "headline": "Uber Among Top Profit Beats, But Apple Among The Worst",
    "summary": "Uber Among Top Profit Beats, But Apple Among The Worst",
    "url": "https://finnhub.io/api/news?id=e2be771821f0640110e8a33d4dd74377e651f133ea243eb11095d62699a9a02d",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731400222,
      "headline": "Uber Among Top Profit Beats, But Apple Among The Worst",
      "id": 131412987,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "Uber Among Top Profit Beats, But Apple Among The Worst",
      "url": "https://finnhub.io/api/news?id=e2be771821f0640110e8a33d4dd74377e651f133ea243eb11095d62699a9a02d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’",
    "summary": "As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.",
    "url": "https://finnhub.io/api/news?id=92763d3415acb529e629a686d3c0858d84b88fd4439ab3a4286da2a7aef0ecde",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731398400,
      "headline": "Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’",
      "id": 131309555,
      "image": "https://imgproxy.divecdn.com/ecZ2Ya1kX97Z-QZj8BxhlqAsDqSzIDw2bCHnGESWZo4/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL1BmaXplcl9IUV9FbnRyYW5jZS5qcGc=.webp",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.",
      "url": "https://finnhub.io/api/news?id=92763d3415acb529e629a686d3c0858d84b88fd4439ab3a4286da2a7aef0ecde"
    }
  }
]